Lance McMahon, Jr

Lance McMahon, Jr, Ph.D., M.S.

Chair And Professor

Department: Pharmacodynamics
Business Phone: (352) 294-8878
Business Email: lance.mcmahon@cop.ufl.edu

About Lance McMahon, Jr

Dr. McMahon is Professor and Chair of the Department of Pharmacodynamics at the University of Florida College of Pharmacy. He previously held the position of Tenured Associate Professor of Pharmacology at the University of Texas Health Science Center in San Antonio. He obtained a PhD in Behavioral Neuroscience from Texas A&M University, and was a postdoctoral fellow in the Department of Pharmacology and Toxicology at the University of Texas Medical Branch in Galveston. He has been continuously funded by the National Institute on Drug Abuse since 2002 as PI of 6 R01 grants, an R21, and a U grant for a total of $22M in funding. He is a regular member of the Center for Scientific Review NIH study section Biobehavioral Regulation, Learning and Ethology. He served on the Executive Board of the Behavioral Pharmacology Division of the American Society of Pharmacology and Experimental Therapeutics. Dr. McMahon’s laboratory integrates principles of behavior and receptor theory to identify CNS mechanisms responsible for drug dependence, and novel pharmacological strategies that maximize therapeutics and minimize abuse liability.

Accomplishments

Scientific Programming Committee
2019-2020 · American Association of Pharmaceutical Scientists
Guest Editor
2019-2020 · Pharmacology Biochemistry and Behavior
Internal Scientific Advisory Committee
2018-Current · Center for Addiction Research and Education
Executive Committee
2018-Current · UF Health Neuroscience and Neuromedicine Research
Regular Member, Biobehavioral Regulation Learning and Ethology Study Section
2017-2021 · NIH Center for Scientific Review
Executive Board
2017-2018 · Texas Research Society on Alcoholism
Executive Committee
2009-2011 · Division of Behavioral Pharmacology, American Society of Pharmacology and Experimental Therapeutics
Scientific Programming Committee
2008-2011 · College on Problems of Drug Dependence
Field Editor
2006-2017 · International Journal of Neuropsychopharmacology

Research Profile

Research in my laboratory integrates principles of behavior and receptor theory to identify central nervous system mechanisms responsible for drug dependence. We also investigate novel pharmacological strategies that maximize therapeutic potential and minimize abuse and dependence liability. We combine behavioral and physiological approaches, receptor-selective ligands, and quantitative analyses of drug interactions. We are interested in several pharmacological classes of abused drugs.

Cannabinoids, for example, include cannabis-derived tetrahydrocannabinols, numerous synthetic cannabinoids, and endogenous cannabinoid neurotransmitters. We systematically compare the effects of cannabinoids and evaluate underlying receptor mechanisms to better understand dependence and therapeutic potential.

Cholinergic drugs of interest include FDA-approved smoking cessation aids such as nicotine, varenicline, and bupropion. We compare the effects of smoking cessation aids and investigational nicotinic acetylcholine receptor drugs to better understand relationships between nicotinic acetylcholine receptor subtypes, intrinsic activity (i.e., efficacy), and behavioral effects. Most recently, we are joining investigators in the Departments of Medicinal Chemistry (McCurdy), Pharmaceutics (Avery), and Pharmacodynamics (McLaughlin, Peris) to evaluate the in vitro and in vivo pharmacology of kratom and its derivatives which have proven therapeutic utility in the reduction of opioid dependence.

Publications

2021
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method.
Journal of pharmaceutical and biomedical analysis. 194 [DOI] 10.1016/j.jpba.2020.113778. [PMID] 33277117.
2020
Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-β-erythroidine in nicotine-tolerant mice.
Brain and behavior. 10(4) [DOI] 10.1002/brb3.1581. [PMID] 32092237.
2020
The discriminative stimulus effects of epibatidine in C57BL/6J mice.
Behavioural pharmacology. 31(6):565-573 [DOI] 10.1097/FBP.0000000000000555. [PMID] 32209809.
2020
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
2020
Pharmacokinetics and Safety of Mitragynine in Beagle Dogs.
Planta medica. 86(17):1278-1285 [DOI] 10.1055/a-1212-5475. [PMID] 32693425.
2020
Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives.
Molecular pharmacology. 98(4):328-342 [DOI] 10.1124/molpharm.120.000037. [PMID] 32690626.
2020
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.
Pharmacological reviews. 72(2):527-557 [DOI] 10.1124/pr.119.018028. [PMID] 32205338.
2020
Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy.
ACS pharmacology & translational science. 3(6):1063-1068 [DOI] 10.1021/acsptsci.0c00075. [PMID] 33344889.
2020
Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
Neuropharmacology. 168 [DOI] 10.1016/j.neuropharm.2020.108008. [PMID] 32113032.
2020
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.
Toxicology letters. 319:148-154 [DOI] 10.1016/j.toxlet.2019.11.005. [PMID] 31707106.
2020
Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.
Drug and alcohol dependence. 215 [DOI] 10.1016/j.drugalcdep.2020.108235. [PMID] 32889450.
2020
Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use.
Frontiers in psychiatry. 11 [DOI] 10.3389/fpsyt.2020.574483. [PMID] 33324252.
2020
Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis. 180 [DOI] 10.1016/j.jpba.2019.113019. [PMID] 31838282.
2020
Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery.
ChemMedChem. 15(9):728-732 [DOI] 10.1002/cmdc.202000025. [PMID] 32061146.
2020
Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain.
Neuroscience letters. 731 [DOI] 10.1016/j.neulet.2020.135029. [PMID] 32380144.
2020
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
Journal of medicinal chemistry. 63(1):433-439 [DOI] 10.1021/acs.jmedchem.9b01465. [PMID] 31834797.
2019
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
PloS one. 14(3) [DOI] 10.1371/journal.pone.0209947. [PMID] 30861005.
2019
The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.
The Journal of pharmacology and experimental therapeutics. 370(3):380-389 [DOI] 10.1124/jpet.118.255844. [PMID] 31235534.
2019
The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
Psychopharmacology. 236(9):2725-2734 [DOI] 10.1007/s00213-019-05247-7. [PMID] 31098655.
2019
Pharmacological characterization of mitragynine, the primary constituent in Kratom, as a potential medication for opioid use disorder.
Journal of pharmacological and toxicological methods. 99 [DOI] 10.1016/j.vascn.2019.05.012. [PMID] 31963089.
2019
Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.
Expert review of clinical pharmacology. 12(3):189-195 [DOI] 10.1080/17512433.2019.1570844. [PMID] 30650314.
2019
Kratom policy: The challenge of balancing therapeutic potential with public safety.
The International journal on drug policy. 70:70-77 [DOI] 10.1016/j.drugpo.2019.05.003. [PMID] 31103778.
2019
Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.
Pharmacology, biochemistry, and behavior. 179:27-33 [DOI] 10.1016/j.pbb.2019.02.002. [PMID] 30738085.
2019
Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.
Behavioural pharmacology. 30(5):412-421 [DOI] 10.1097/FBP.0000000000000452. [PMID] 30398980.
2019
Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.
Drug development and industrial pharmacy. 45(5):861-867 [DOI] 10.1080/03639045.2019.1578787. [PMID] 30712397.
2018
Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.
Experimental and clinical psychopharmacology. 26(6):541-548 [DOI] 10.1037/pha0000226. [PMID] 30102063.
2017
The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.
Neuropharmacology. 116:9-17 [DOI] 10.1016/j.neuropharm.2016.12.003. [PMID] 27940077.
2017
The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
Psychopharmacology. 234(5):781-792 [DOI] 10.1007/s00213-016-4514-4. [PMID] 28028600.
2017
Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
The Journal of pharmacology and experimental therapeutics. 362(2):278-286 [DOI] 10.1124/jpet.117.240572. [PMID] 28533288.
2016
Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.
Drug and alcohol dependence. 165:87-93 [DOI] 10.1016/j.drugalcdep.2016.05.016. [PMID] 27289270.
2016
Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.
British journal of pharmacology. 173(24):3454-3466 [DOI] 10.1111/bph.13635. [PMID] 27667659.
2016
Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.
European journal of pharmacology. 786:169-178 [DOI] 10.1016/j.ejphar.2016.05.032. [PMID] 27238974.
2016
Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.
Behavioural pharmacology. 27(2-3 Spec Issue):240-8 [DOI] 10.1097/FBP.0000000000000233. [PMID] 26910582.
2015
Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
The Journal of pharmacology and experimental therapeutics. 354(2):111-20 [DOI] 10.1124/jpet.115.222851. [PMID] 25998048.
2015
Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
The Journal of pharmacology and experimental therapeutics. 353(2):261-8 [DOI] 10.1124/jpet.115.222836. [PMID] 25711338.
2015
The rise (and fall?) of drug discrimination research.
Drug and alcohol dependence. 151:284-8 [PMID] 26207268.
View on: PubMed
2014
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure.
Drug and alcohol dependence. 139:1-8 [DOI] 10.1016/j.drugalcdep.2014.02.696. [PMID] 24703610.
2014
Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.
Psychopharmacology. 231(23):4455-66 [DOI] 10.1007/s00213-014-3589-z. [PMID] 24800895.
2014
JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.
European journal of pharmacology. 740:151-9 [DOI] 10.1016/j.ejphar.2014.06.023. [PMID] 24972243.
2014
The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
European journal of pharmacology. 727:35-42 [DOI] 10.1016/j.ejphar.2014.01.041. [PMID] 24486701.
2014
The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.
Behavioural pharmacology. 25(4):296-305 [DOI] 10.1097/FBP.0000000000000054. [PMID] 24978703.
2013
Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.
Psychopharmacology. 228(2):321-33 [DOI] 10.1007/s00213-013-3037-5. [PMID] 23494230.
2012
Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
Psychopharmacology. 222(3):425-38 [DOI] 10.1007/s00213-012-2661-9. [PMID] 22374253.
2012
JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
The Journal of pharmacology and experimental therapeutics. 340(1):37-45 [DOI] 10.1124/jpet.111.187757. [PMID] 21965552.
2012
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 341(3):840-9 [DOI] 10.1124/jpet.112.193078. [PMID] 22438471.
2012
Purity of synthetic cannabinoids sold online for recreational use.
Journal of analytical toxicology. 36(1):66-8 [DOI] 10.1093/jat/bkr018. [PMID] 22290755.
2012
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice.
Progress in neuro-psychopharmacology & biological psychiatry. 38(2):260-9 [DOI] 10.1016/j.pnpbp.2012.04.011. [PMID] 22542870.
2012
Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 342(3):843-9 [DOI] 10.1124/jpet.112.196444. [PMID] 22718500.
2011
Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
British journal of pharmacology. 162(5):1060-73 [DOI] 10.1111/j.1476-5381.2010.01116.x. [PMID] 21091643.
2011
The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
European journal of pharmacology. 654(1):47-52 [DOI] 10.1016/j.ejphar.2010.12.003. [PMID] 21172344.
2011
The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.
British journal of pharmacology. 164(2b):655-66 [DOI] 10.1111/j.1476-5381.2011.01388.x. [PMID] 21449917.
2011
Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Psychopharmacology. 215(4):665-75 [DOI] 10.1007/s00213-010-2162-7. [PMID] 21246187.
2010
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson’s disease and abuse liability.
Prostaglandins & other lipid mediators. 91(3-4):90-103 [DOI] 10.1016/j.prostaglandins.2009.05.004. [PMID] 19523530.
2010
Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection.
Journal of chromatographic science. 48(6):491-5 [PMID] 20822666.
View on: PubMed
2010
Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
The Journal of pharmacology and experimental therapeutics. 334(1):347-56 [DOI] 10.1124/jpet.110.168435. [PMID] 20375197.
2009
Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
Psychopharmacology. 203(2):219-28 [DOI] 10.1007/s00213-008-1230-8. [PMID] 18592221.
2009
Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
International review of psychiatry (Abingdon, England). 21(2):134-42 [DOI] 10.1080/09540260902782786. [PMID] 19367507.
2009
Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys.
Psychopharmacology. 203(2):411-20 [DOI] 10.1007/s00213-008-1242-4. [PMID] 18636243.
2008
Acute cross tolerance to midazolam, and not pentobarbital and pregnanolone, after a single dose of chlordiazepoxide in monkeys discriminating midazolam.
Behavioural pharmacology. 19(8):796-804 [DOI] 10.1097/FBP.0b013e32831c3b40. [PMID] 19020414.
2008
Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
Psychopharmacology. 198(4):487-95 [PMID] 17673980.
View on: PubMed
2008
Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Psychopharmacology. 195(4):479-86 [PMID] 17874317.
View on: PubMed
2008
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Psychopharmacology. 199(2):199-208 [DOI] 10.1007/s00213-008-1157-0. [PMID] 18470505.
2007
Changes in relative potency among positive GABA(A) receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys.
Psychopharmacology. 192(1):135-45 [PMID] 17245585.
View on: PubMed
2007
Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
European journal of pharmacology. 569(1-2):70-6 [PMID] 17553486.
View on: PubMed
2006
Efficacy and the discriminative stimulus effects of negative GABAA modulators, or inverse agonists, in diazepam-treated rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 318(2):907-13 [PMID] 16705082.
View on: PubMed
2006
Differential behavioral effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys.
British journal of pharmacology. 147(3):260-8 [PMID] 16331290.
View on: PubMed
2006
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
Psychopharmacology. 188(3):306-14 [PMID] 16953389.
View on: PubMed
2006
Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies.
Behavioral neuroscience. 120(3):535-41 [PMID] 16768605.
View on: PubMed
2006
Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
The Journal of pharmacology and experimental therapeutics. 319(3):1211-8 [PMID] 16943255.
View on: PubMed
2005
Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys.
Psychopharmacology. 178(4):400-9 [PMID] 15765255.
View on: PubMed
2005
Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine.
Pharmacology, biochemistry, and behavior. 81(3):626-34 [PMID] 15946731.
View on: PubMed
2005
Inez Beverly Prosser and the education of African Americans.
Journal of the history of the behavioral sciences. 41(1):43-62 [PMID] 15635704.
View on: PubMed
2005
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys.
Behavioural pharmacology. 16(1):53-8 [PMID] 15706138.
View on: PubMed
2005
Negative GABA(A) modulators attenuate the discriminative stimulus effects of benzodiazepines and the neuroactive steroid pregnanolone in rhesus monkeys.
Psychopharmacology. 181(4):697-705 [PMID] 15983789.
View on: PubMed
2005
Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression.
Behavioral neuroscience. 119(5):1173-83 [PMID] 16300424.
View on: PubMed
2005
SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
Behavioural pharmacology. 16(5-6):363-72 [PMID] 16148440.
View on: PubMed
2004
Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 308(1):111-9 [PMID] 14569055.
View on: PubMed
2003
Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys.
Psychopharmacology. 165(3):222-8 [PMID] 12434260.
View on: PubMed
2003
Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens.
Neuropharmacology. 44(3):342-53 [PMID] 12604093.
View on: PubMed
2003
Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys.
European journal of pharmacology. 466(1-2):113-20 [PMID] 12679147.
View on: PubMed
2003
Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone.
The Journal of pharmacology and experimental therapeutics. 306(3):1167-73 [PMID] 12766254.
View on: PubMed
2003
Discriminative stimulus effects of positive GABAA modulators and other anxiolytics, sedatives, and anticonvulsants in untreated and diazepam-treated monkeys.
The Journal of pharmacology and experimental therapeutics. 304(1):109-20 [PMID] 12490581.
View on: PubMed
2003
Discriminative stimulus effects of (-)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands.
Drug and alcohol dependence. 70(3):255-64 [PMID] 12757963.
View on: PubMed
2003
Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
Experimental and clinical psychopharmacology. 11(4):286-93 [PMID] 14599262.
View on: PubMed
2002
Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys.
Behavioural pharmacology. 13(7):545-55 [PMID] 12409993.
View on: PubMed
2002
Daily treatment with diazepam differentially modifies sensitivity to the effects of gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 300(3):1017-25 [PMID] 11861811.
View on: PubMed
2002
Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics. 300(2):505-12 [PMID] 11805210.
View on: PubMed
2001
Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats.
The Journal of pharmacology and experimental therapeutics. 297(1):357-63 [PMID] 11259563.
View on: PubMed
2001
Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 21(19):7781-7 [PMID] 11567068.
View on: PubMed
2001
Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys.
The Journal of pharmacology and experimental therapeutics. 298(3):1227-35 [PMID] 11504825.
View on: PubMed
2001
Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 24(3):319-29 [PMID] 11166521.
View on: PubMed
2001
The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.
Psychopharmacology. 158(3):289-96 [PMID] 11713619.
View on: PubMed
1999
Antagonism of 5-hydroxytryptamine(4) receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine(4) receptors in the nucleus accumbens shell.
The Journal of pharmacology and experimental therapeutics. 291(1):300-7 [PMID] 10490917.
View on: PubMed
1999
Effects of ephedrine enantiomers on conditioned taste aversion and kaolin intake in rats.
Pharmacology, biochemistry, and behavior. 63(1):119-24 [PMID] 10340531.
View on: PubMed
1998
Repeated administration of ephedrine induces behavioral sensitization in rats.
Psychopharmacology. 140(1):52-6 [PMID] 9862402.
View on: PubMed
1998
Effects of (-)-ephedrine on locomotion, feeding, and nucleus accumbens dopamine in rats.
Psychopharmacology. 135(2):133-40 [PMID] 9497018.
View on: PubMed
1998
PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats.
The American journal of physiology. 274(1):R23-9 [DOI] 10.1152/ajpregu.1998.274.1.R23. [PMID] 9458894.
1997
Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats.
Pharmacology, biochemistry, and behavior. 57(4):767-70 [PMID] 9259004.
View on: PubMed
1997
Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide.
Pharmacology, biochemistry, and behavior. 58(3):673-7 [PMID] 9329057.
View on: PubMed
1997
Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats.
Pharmacology, biochemistry, and behavior. 57(1-2):281-4 [PMID] 9164583.
View on: PubMed
1996
Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus
Physiology & Behavior. 59(1):63-69 [DOI] 10.1016/0031-9384(95)02032-2. [PMID] 8848492.
1996
Induction of parturition in ewes with dexamethasone or dexamethasone and cloprostenol.
The Canadian veterinary journal = La revue veterinaire canadienne. 37(2):101-2 [PMID] 8640645.
View on: PubMed
1995
Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats.
Pharmacology, biochemistry, and behavior. 50(2):287-91 [PMID] 7740069.
View on: PubMed
1994
Conditioned taste aversion in rats induced by the alpha 1-adrenoceptor agonist cirazoline.
Pharmacology, biochemistry, and behavior. 48(3):601-4 [PMID] 7938112.
View on: PubMed
1994
Conditioned taste aversion in rats induced by the alpha1- adrenoceptor agonist cirazoline
Pharmacology Biochemistry and Behavior. 48:601-604
1993
Modulation of feeding by hypothalamic paraventricular nucleus alpha1- and alpha2-adrenergic receptors
Life Sciences. 53:669-679 [DOI] 10.1016/0024-3205(93)90243-V.
1993
Effects on food and water intake of the alpha1-adrenoceptor agonists amidephrine and SK&F-89748
Life Sciences. 53(2):169-174 [DOI] 10.1016/0024-3205(93)90664-o. [PMID] 8100042.

Grants

Dec 2020 ACTIVE
Opioid use disorders: UF Pharmacy medications discovery and development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Jun 2019 ACTIVE
Opioid and cannabinoid interactions in pain and reward
Role: Co-Investigator
Funding: UF RESEARCH
Apr 2019 ACTIVE
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Dec 2018 – Nov 2020
Opioid use disorders: UF Pharmacy medications discovery and development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Oct 2017 – Jun 2019
Nicotine dependence: neuropharmacology in monkeys
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA

Education

Ph.D.
1997 · Texas A&M University
M.S.
1994 · Texas A&M University
B.A.
1992 · University of Pennsylvania

Teaching Profile

Courses Taught
2018-2020
PHA6910 Supervised Research
2019-2020
PHA6935 Selected Topics in Pharmacy
2019
PHA7979 Advanced Research
2019
PHA7980 Research for Doctoral Dissertation
2018
PHA6512L Experiential Research Training in Pharmacodynamics

Contact Details

Phones:
Business:
(352) 294-8878
Emails:

Recent News

10/10: All pharmacodynamics tenure-track faculty are federally funded

The awards come from various federal institutions, but all 10 have at least one grant from the National Institutes of Health, or NIH.

Cannabidiol: Rising star or popular fad?

Drs. Lance McMahon and Jenny Wilkerson author a story for The Conversation about the rising popularity and the scientific interest in cannabidiol.

UF College of Pharmacy receives $3.5 million NIDA grant to bolster kratom research

The grant will bolster research on Mitragyna speciosia, or kratom, and its potential to treat opioid misuse and physical dependence.

Dr. Lance McMahon shares expertise on panel discussing psychedelic use to treat psychiatric conditions

The event was hosted by the Office of the Vice President for Research and Education at University of Florida Health and featured five panelists.

Read more